Clinical trial NCT01743820 - References

Malaria — Phase2a Primaquine Dose Escalation Study

Citation(s)

•   Baird JK, Schwartz E, Hoffman SL
  Prevention and treatment of vivax malaria. Curr Infect Dis Rep. 2007 Jan;9(1):39-46.
•   El-Sayed B, El-Zaki SE, Babiker H, Gadalla N, Ageep T, Mansour F, Baraka O, Milligan P, Babiker A
  A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One. 2007 Dec 12;2(12):e1311.
•   Gosling RD, Okell L, Mosha J, Chandramohan D
  The role of antimalarial treatment in the elimination of malaria. Clin Microbiol Infect. 2011 Nov;17(11):1617-23. doi: 10.1111/j.1469-0691.2011.03660.x. Epub 2011 Sep 26. Review.
•   Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, Sauerwein RW, Bousema T
  In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother. 2010 May;54(5):1762-8. doi: 10.1128/AAC.01135-09. Epub 2010 Mar 1.
•   WHO (2010) Guidelines for the treatment of malaria, Second edition
  Geneva: World Health Organization
•   WHO (2011) World Malaria Report 2011
  Geneva: World Health Organization.

Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia

Details for clinical trial NCT01743820